An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension

Journal of Glaucoma

Volumn 22, Issue 9, 2013, Pages 707-712

  Digiuni, Maurizio ^a   Manni, Gianluca ^b   Vetrugno, Michele ^d   Uva, Maurizio ^e   Milano, Giovanni ^f   Orzalesi, Nicola ^a   Fogagnolo, Paolo ^c   Centofanti, Marco ^b,c   Campos, Emilio ^g   Rossetti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c IRCCS FONDAZIONE BIETTI   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

clinical trial; latanoprost; medical therapy; ocular hypertension; primary open angle glaucoma

Indexed keywords

LATANOPROST; ANTIHYPERTENSIVE AGENT; EYE DROPS; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE HYPEREMIA; EYE IRRITATION; EYELASHES GROWTH; FEMALE; HAIR GROWTH; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PROSPECTIVE STUDY; THERAPEUTIC EQUIVALENCE;

AGED; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; THERAPEUTIC EQUIVALENCY; TONOMETRY, OCULAR;

EID: 84890567225     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318259b47c     Document Type: Article

References (19)

1. Magnitude and causes of visual impairment. Fact sheet no. 282, November 2004. Available at: Http//www.who.int/media centre/factsheets/fs282/en/. Accessed on February 8, 2006
2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120: 1268-1279
3. The Advanced Glaucoma Intervention Study (AGIS). The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130: 429- 440
4. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and glaucoma: Meta-Analysis of randomised control trials. BMJ. 2005;331: 134-139
5. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-Analysis of randomized clinical trials. Ophthalmology. 2005;112: 1177-1185
6. Foganolo P, Rossetti L. Medical treatment of glaucoma: Present and future. Expert Opin Investig Drugs. 2011;20: 947-959
7. Villumsen J, Alm A-A. PhXA34 - A prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol. 1992;76: 214-217
8. Camras CB, Schumer RA, Marks A, et al. Intraocular pressure reduction with pHXA34, a new prostaglandin analogue in patients with ocular hypertension. Arch Ophthalmol. 1992; 110: 1733-1738
9. Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996;7: 11-17
10. Camras CB, United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. Ophthalmology. 1996;103: 138-147
11. Orzalesi N, Rossetti L, Invernizzi T, et al. The effect of timolol, latanoprost, and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41: 2566-2573
12. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effect of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113: 239-246
13. Strmen P, Jancus V, Okkelovà J. Clinical trial of the generic product Unilat following the efficiency and safety in glaucoma and intraocular hypertension. Cesk Slov Oftalmol. 2010;66: 258-261
14. Narayanaswamy A, Neoq A, Baskaran M, et al. A randomised, cross over, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic latanoprost (Latanoprost) in subjects with open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55: 127-131
15. Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effect of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology. 1995;102: 1743-1752
16. Gaton DD, Ehrenberg M, Lusky M, et al. Effect of repeated applanation tonometry on the accuracy of intraocular pressure measurements. Curr Eye Res. 2010;35: 475-479
17. List of reimbursable equivalent drugs by active principle, Ministry of Health, AIFA - Italian Medicine Agency; February 15, 2012
18. Kahook MY, Fechtner RD, Katz LJ, et al. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography- Tandem mass spectrometry. Curr Eye Res. 2012;37: 101-108
19. Directive 2001/83/EC Of The European Parliament And Of The Council of November 6, 2001, on the Community code relating to medicinal products for human use. 20. Guideline On The Investigation Of Bioequivalence (CPMP/ EWP/QWP/1401/98 Rev. 1), January 2010